Cotherix
San Francisco
About Cotherix
Cotherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis, our lead product candidate, is an inhaled formulation of iloprost.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Total funding: $55.0M
- Funding stage: M&A
- Last round: Series C (Oct 2003)
- Ticker: nasdaq:CTRX
- Website: cotherix.com
Industries & Categories
Biotechnology, Finance, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/cotherix-547111 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.